Kardigan, Inc. Common Stock (KARD) - Net Assets
Based on the latest financial reports, Kardigan, Inc. Common Stock (KARD) has net assets worth $615.52 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($721.79 Million) and total liabilities ($106.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kardigan, Inc. Common Stock (KARD) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $615.52 Million |
| % of Total Assets | 85.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Kardigan, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Kardigan, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Kardigan, Inc. Common Stock (KARD) total market value.
Annual Net Assets for Kardigan, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Kardigan, Inc. Common Stock from 2024 to 2025. Also explore net asset growth rate of Kardigan, Inc. Common Stock to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-250.34 Million | -200.91% |
| 2024-12-31 | $-83.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kardigan, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19194100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $63.00K | % |
| Other Components | $30.69 Million | % |
| Total Equity | $-250.34 Million | 100.00% |
Kardigan, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Kardigan, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Integral Ad Science Holding LLC
NASDAQ:IAS
|
$1.74 Billion |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
$1.74 Billion |
|
Tri Continental Closed Fund
NYSE:TY
|
$1.74 Billion |
|
H2O America
NASDAQ:HTO
|
$1.74 Billion |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
$1.74 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
$1.73 Billion |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
$1.73 Billion |
|
SRH Total Return Fund Inc.
NYSE:STEW
|
$1.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kardigan, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -83,194,000 to -250,335,000, a change of -167,141,000.
- Net loss of 191,941,000 reduced equity.
- New share issuances of 453,608,000 increased equity.
- Other comprehensive income increased equity by 63,000.
- Other factors decreased equity by 428,871,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-191.94 Million | -76.67% |
| Share Issuances | $453.61 Million | +181.2% |
| Other Comprehensive Income | $63.00K | +0.03% |
| Other Changes | $-428.87 Million | -171.32% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kardigan, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-0.93 | $18.56 | x |
| 2025-12-31 | $-4.18 | $18.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kardigan, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-80.34 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-166.91 Million |
Industry Comparison
This section compares Kardigan, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kardigan, Inc. Common Stock (KARD) | $615.52 Million | 0.00% | 0.17x | $1.74 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more